IM-101 for generalized and ocular myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new medicine called IM-101 in people with myasthenia gravis (MG), a muscle weakness condition. It aims to see if it can safely help manage symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 74 years old.
- You must have a diagnosis of myasthenia gravis (MG).
- You must be on a stable dose of your current MG medications.
- You must weigh at least 40 kilograms (about 88 pounds).
- You must have had vaccines for meningitis, pneumonia, and Hib (a bacterial infection).
- You must not have had a cancer diagnosis or malignant thymoma in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial studies nipocalimab, an immune-focused medicine, to see if it can improve generalized myasthenia gravis (gMG) in children ages 2 to under 18. It may help reduce weakness caused by this autoimmune muscle disease, but you must meet specific antibody and health requirements.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.